상세 보기
Major Depressive Disorder: Rethinking and Understanding Recent Discoveries
- Park, S.-C.;
- Kim, Y.-K.
초록
The Diagnostic and Statistical Manual of Mental Disorder, Fourth Edition (DSM-IV) was revised based on a combination of a categorical and a dimensional approach such that in the DSM, Fifth Edition (DSM-5), depressive disorders have been separated as a distinctive disease entity from bipolar disorders, consistent with the deconstruction of Kraepelinian dualism. Additionally, the diagnostic thresholds of depressive disorders may be reduced due to the addition of “hopelessness” to the subjective descriptors of depressed mood and the removal of the “bereavement exclusion.” Manic/hypomanic, psychotic, and anxious symptoms in major depressive disorder (MDD) and other depressive disorders are described using the transdiagnostic specifiers of “with mixed features,” “with psychotic features,” and “with anxious distress,” respectively. Additionally, due to the polythetic and operational characteristics of the DSM-5 diagnostic criteria, the heterogeneity of MDD is inevitable. Thus, 227 different symptom combinations fulfill the DSM-5 diagnostic criteria for MDD. This heterogeneity of MDD is criticized in view of the Wittgensteinian analogy of language game. Depression subtypes determined by disturbances in monoamine levels and the severity of the disease have been identified in the literature. According to a review of the Gottesman and Gould criteria, neuroticism, morning cortisol, cortisol awakening response, asymmetry in frontal cortical activity on electroencephalography (EEG), and probabilistic reward learning, among other variables, are evidenced as endophenotypes for depressive disorders. Network analysis has been proposed as a potential method to compliment the limitations of current diagnostic criteria and to explore the pathways between depressive symptoms, as well as to identify novel and interesting relationships between depressive symptoms. Based on the literature on network analysis in this field, no differences in the centrality index of the DSM and non-DSM symptoms were repeatedly present among patients with MDD. Furthermore, MDD and other depressive syndromes include two of the Research Domain Criteria (RDoC), including the Loss construct within the Negative Valence Systems domains and various Reward constructs within the Positive Valence Systems domain. © 2021, Springer Nature Singapore Pte Ltd.
- 제목
- Major Depressive Disorder: Rethinking and Understanding Recent Discoveries
- 저자
- Park, S.-C.; Kim, Y.-K.
- 발행일
- 2021-04
- ISBN
- 978-981-33-6043-3
- 언어
- ENG
- 출판사
- Kluwer Academic/Plenum Publishers
- 목차
- Part I Re-thinking Depression from a Network Perspective 1. Phenotype Network and Brain Structural Covariance Network of Major Depression - page 3 2. Task MRI-Based Functional Brain Network of Major Depression - page 19 3. White Matter-Based Structural Brain Network of Major Depression - page 35 4. The Application of a Machine Learning-Based Brain MRI Approach in Major Depression - page 57 5. Common Currency Between Experience and Brain Spatiotemporal Psychopathology of the Resting State in Depression - page 71 6. Development of Neuroimaging-Based Biomarkers in Major Depression - page 85 Part II Current Diagnostic and Neurobiological Issues 7. Challenges and Strategies for Current Classifications of Depressive Disorders Proposal for Future Diagnostic Standards - page 103 8. Epigenetics A Missing Link Between Early Life Stress and Depression - page 117 9. From Leaky Gut to Impaired Glia-Neuron Communication in Depression - page 129 10. Neurogenesis and Neuroplasticity in Major Depression Its Therapeutic Implication - page 157 11. A Load to Find Clinically Useful Biomarkers for Depression - page 175 12. Genetic Architecture of Depression Where Do We Stand Now - page 203 13. Pharmacogenetic Pharmacogenomic Tests for Treatment Prediction in Depression - page 231 14. The Role of Neurotrophic Factors in Pathophysiology of Major Depressive Disorder - page 257 Part III Current Specific Treatments for Depression 15. Clinical Application of Real-Time fMRI-Based Neurofeedback for Depression - page 275 16. Cognitive Behavioral Therapy and Mindfulness-Based Cognitive Therapy for Depressive Disorders - page 295 17. Acceptance and Commitment Therapy for Major Depressive Disorder Insights into a New Generation of Face-to-Face Treatment and Digital Self-Help Approaches - page 311 18. Current Updates on Newer Forms of Transcranial Magnetic Stimulation in Major Depression - page 333 19. Well-being Therapy in Depressive Disorders - page 351 20. Current Research on Complementary and Alternative Medicine CAM in the Treatment of Major Depressive Disorder An Evidence-Based Review - page 375 21. Psychopharmacology Algorithms for Major Depressive Disorder Current Status - page 429 Part IV Promising Future Treatments for Depression 22. Novel Psychopharmacology for Depressive Disorders - page 449 23. Creative Person-Centered Narrative Psychopharmacotherapy of Depression - page 463 24. Induced Pluripotent Stem Cells iPSCs Technology Potential Targets for Depression - page 493 25. Vaccination and Immunotherapy for Major Depression - page 503 26. Psychedelic Medicines in Major Depression Progress and Future Challenges - page 515 27. Precision Psychiatry Biomarker-Guided Tailored Therapy for Effective Treatment and Prevention in Major Depression - page 535